Collections in this community

Recent Submissions

1. Thinking out of the box: revisiting health surveillance based on medical records

   ANTIMICROBIAL STEWARDSHIP AND HEALTHCARE EPIDEMIOLOGY, v.3, n.1, article ID e185, p, 2023

   Despite the considerable advances in the last years, the health information systems for health surveillance still need to overcome some critical issues so that epidemic detection can be performed in real time. For instance, despite the efforts of the Brazilian Ministry of Health (MoH) to make COV...

2. ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial

   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY: GLOBAL, v.2, n.4, article ID 100140, p, 2023

   Background: ABX464 (obefazimod) is a small molecule that upregulates a single microRNA (miR-124) in immune cells and reduces the production of various inflammatory cytokines and chemokines. Objective: We assessed the efficacy and safety of the standard of care (SoC) plus oral obefazimod (SoC plus...

3. Occupational asthma and allergic asthma: differences in the physical activity level, clinical control, and airway inflammation

   EUROPEAN RESPIRATORY JOURNAL, v.62, suppl.67, article ID PA953, 2p, 2023

4. Characteristics and benefits of responders to a behavioral intervention to increase physical activity in asthma: preliminary data from a pragmatic study

   EUROPEAN RESPIRATORY JOURNAL, v.62, suppl.67, article ID PA352, 3p, 2023

5. Effect of adjuvant probiotic therapy (<i>Lactobacillus reuteri</i>) in the treatment of periodontitis associated with diabetes mellitus: clinical, controlled, and randomized study

   CLINICAL ORAL INVESTIGATIONS, v.28, n.1, article ID 80, 14p, 2024

   Objectives Subgingival instrumentation (SI) with probiotics may be a proposal for the treatment of periodontitis (P), for patients with type 2 diabetes mellitus (T2DM). The Lactobacillus reuteri probiotic as an adjunctive therapy in the treatment of P associated with T2DM was evaluated.Materials ...

6. Parasite DNA and Markers of Decreased Immune Activation Associate Prospectively with Cardiac Functional Decline over 10 Years among <i>Trypanosoma cruzi</i> Seropositive Individuals in Brazil

   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v.25, n.1, article ID 44, 9p, 2024

   Parasitemia and inflammatory markers are cross-sectionally associated with chronic Chagas cardiomyopathy (CCC) among patients with Trypanosoma cruzi. However, the prospective association of the parasite load and host immune response-related characteristics with CCC (that is, progressors) among T....

7. Vaccines past and future - a Brazilian perspective

   BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, v.207, n.9, p.1212-1217, 2023

   In this opinion article, I provide a brief history of vaccine development, commenting on the classic ways of obtaining vaccines using the infectious agent itself. Then, I address the issue of viral vaccines, their successes , difficulties, discussing the issue of viral serotypes. Bacterial vaccin...

8. Fructose biphosphate aldolase: A new cassava allergen

   WORLD ALLERGY ORGANIZATION JOURNAL, v.16, n.12, article ID 100845, 11p, 2023

   Background: Food allergy has considerably increased in recent years and this situation has been aggravated mainly by the consumption of more processed and complex foods, since minor or potentially allergenic foods are not required to be labeled. Manihot esculenta (cassava) is a widely consumed fo...

9. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

   NEW ENGLAND JOURNAL OF MEDICINE, v.385, n.19, p.1774-1785, 2021

   BACKGROUND At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 (Covid-19). After emergency use of the vaccine was authorized, the protocol was amended to include an open-label pha...

10. COVID-19 mechanisms on cardio-vascular dysfunction: from membrane receptors to immune response, volume II

    FRONTIERS IN CARDIOVASCULAR MEDICINE, v.10, article ID 1278067, 3p, 2023